Drugs Made In America Acquisition Corp. (DMAAR) Stock Price, Financials & Summary

Price chart

Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 15Sep 18

Key dataSep 18, 2026

Open$0.11

From 52W high−45.04%

Volume386.00

Market cap$2.91M

P/E (TTM)0.6x

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$0.11

From 52W high

−45.04%

Volume

386.00

Market cap

$2.91M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.5x

P/E (TTM)

0.6x

RSI (14)

45.8

MomentumView details →

1D Return

+0.00%

YTD Return

−32.51%

SummaryUpdated Jun 1, 2026

Drugs Made In America Acquisition Corp. (NASDAQ:DMAAU) is a special purpose acquisition company (SPAC) founded on May 23, 2024, and headquartered in Fort Lauderdale, Florida. The company went public on January 27, 2025, as a blank check company designed to identify and merge with or acquire businesses in the pharmaceutical and healthcare sectors. As a newly formed entity, DMAAU operates as an investment vehicle seeking to complete a business combination with one or more target companies, with a particular focus on businesses involved in domestic pharmaceutical manufacturing and related healthcare services.

Ask drillr about Drugs Made In America Acquisition Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

0.6x

EV/EBITDA

−1.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

4.42%

ROA (TTM)

4.15%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−99.85%

FCF YoY

+46.96%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+439.29%

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

−32.51%

1Y Return

−41.94%

RSI (14)

45.8

vs 50D SMA

−9.54%

vs 200D SMA

+1.09%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

0.02x

Quick Ratio

0.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

6.09M

Op. CF (TTM)

−323129.00

Latest newsMore news →

Drugs Made In America Acquisition Corp. entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp, fixing a closing valuation of US$2.85 billion for the merger.6d ago

Similar companies

Iron Dome Acquisition I Corp.IDACW ClearThink 1 Acquisition Corp. RightsCTAAR Forefront Tech Holdings Acquisition CorpFTHAW RMG ML Sports HoldingsSHOTR Aeon Acquisition I Corp.AESPR A SPAC II Acquisition CorporationASCB Find similar companies →

Latest newsMore news →